Median progression-free survival was 6.2 months and 4.8 months, respectively (p= 0.00031). While AstraZeneca has since posted its own fair share of flops, the latest approval is based on data from the successful POSEIDON trial, which showed that Imfinzi and Imjudo combined with chemo and maintenance therapy achieved a median overall survival of 14 months compared to 11.7 months in patients on chemotherapy alone followed by maintenance therapy (p= 0.00304). Imjudo was licensed to AstraZeneca by Pfizer in 2011, following some disappointing early results. Imfinzi and Imjudo are approved to treat metastatic NSCLC patients who have no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ![]() ![]() ![]() Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |